piperacillin--tazobactam-drug-combination and Tonsillitis

Tazobactam/piperacillin (TAZ/PIPC) was given intravenously to 15 children with acute bacterial infections including 1 with purulent tonsillitis, 11 with pneumonia, 3 with acute pyelonephritis (2 cases are omitted from evaluation because of Mycoplasma pneumonia and intramuscular injection of gammaglobulin) Daily dosages per kg bodyweight ranging from 132 to 156 mg were given in 3 divided doses per day for 4 to 7 days. Clinical responses were excellent in 7 (54%), good in 6 (46%), fair and poor in 0, with an overall efficacy rate of 100%. Good bacterial responses were obtained in all of the 8 cases from which pathogens were identified. Any side effect was not observed. The above results suggest that TAZ/PIPC is a useful new antibiotic for the treatment of bacterial infections in children.

Topics: Acute Disease; Bacteria; Child; Child, Preschool; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Infant; Infusions, Intravenous; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pyelonephritis; Tonsillitis

Pharmacokinetics, efficacy and safety of tazobactam/piperacillin (TAZ/PIPC), a new beta-lactamase inhibitor combined with a penicillin antibiotic, were studied in pediatrics and the following results were obtained. 1) Serum concentration and urinary excretion of TAZ/PIPC after intravenous administration at a dose of 46 mg/kg to one child were investigated. Serum half-lives were 0.5 hours for TAZ and 0.6 hours for PIPC, while the urinary recovery rates in the first 6 hours after administration, were 61.6% and 56.3% respectively. 2) TAZ/PIPC was administered at a dose of 46.0-73.5 mg/kg t.i.d. for 3-13 days to 10 patients, 6 with respiratory infection, 1 with pharyngotonsillitis, 1 with pertussis and 2 with soft tissue infection of skin. Clinical response were excellent in 5 cases and good in 5 cases, and the efficacy rate was 100%. Bacteriologically, 2 strains (Staphylococcus aureus and Streptococcus pyogenes) isolated from 2 patients were eradicated after the treatment. As for adverse reaction, mild skin rash was observed in 1 case but disappeared within 2 days after withdrawal of the drug. As for abnormal laboratory test results decrease in neutrophiles and increase in eosinophiles in each 1 case were observed, which were, however, normalized after administration. From the above results, tazobactam/piperacillin was considered to be a useful antibiotic in the pediatric field.

Topics: Bacterial Infections; beta-Lactamase Inhibitors; Child; Drug Therapy, Combination; Female; Humans; Infant; Male; Penicillanic Acid; Pharyngitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Respiratory Tract Infections; Staphylococcus aureus; Tonsillitis; Whooping Cough

Topics: Acute Disease; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Humans; Hydrocortisone; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Streptococcal Infections; Streptococcus agalactiae; Tonsillitis